SecBot SecBot
SECBOTREPLAY Home › Report › TXG

TXG · Director John R

10x Genomics, Inc. · 144 filed Sep 3, 2026 at 14:28 ET

At the news

BEARISHIMPACT 4/10

144 filed Sep 3, 2026 at 14:28 ET

Director John R. Stuelpnagel filed a Form 144 notice of intent to sell 20,000 shares of Class A common stock, with an estimated aggregate market value of approximately $1.24 million based on a recent sale price of ~$61.75. The shares were originally granted as founder shares in 2017. This is a relatively small sale relative to the company's $8.0B market cap, but it follows a recent sale of the same number of shares on August 11, 2026, and comes amid elevated insider selling activity (9 sales totaling $4.1M in the past 30 days). The filing signals ongoing insider monetization, though the director's role and modest proportional size limit the bearish signal.

  • Director John R. Stuelpnagel filed Form 144 to sell 20,000 shares of Class A common stock.
  • Estimated aggregate market value of the proposed sale is approximately $1,235,045.87.
  • Shares were originally granted as founder shares on August 21, 2017.
  • A prior sale of 20,000 shares occurred on August 11, 2026, for ~$1,155,032.36.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access